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Meningiomas arise from the meningothelial cells of the arachnoid membranes. They are the most common primary intracranial
neoplasms and represent about 20% of all intracranial tumors. They are usually diagnosed after the third decade of life and they
are more frequent in women than in men. According to the World Health Organization (WHO) criteria, meningiomas can be
classiﬁed into grade I meningiomas, which are benign, grade II (atypical) and grade III (anaplastic) meningiomas, which have
a much more aggressive clinical behaviour. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are routinely
used in the diagnostic workup of patients with meningiomas. Molecular Nuclear Medicine Imaging with Single Photon Emission
Computed Tomography (SPECT) and Positron Emission Tomography (PET) could provide complementary information to CT
and MRI. Various SPECT and PET tracers may provide information about cellular processes and biological characteristics of
meningiomas. Therefore, SPECT and PET imaging could be used for the preoperative noninvasive diagnosis and diﬀerential
diagnosis of meningiomas, prediction of tumor grade and tumor recurrence, response to treatment, target volume delineation
for radiation therapy planning, and distinction between residual or recurrent tumour from scar tissue.
1.Introduction
Meningiomas arise from the meningothelial cells of the
arachnoid membranes, which are attached to the inner layer
of the dura mater [1]. They are the most frequently reported
primary intracranial neoplasms representing about 20% of
all intracranial tumors [2]. They are usually diagnosed after
the third decade of life and they are more frequent in women
than in men accounting for 38% of all intracranial tumors in
women and 20% in men [3].
Meningiomas can be diﬀerentiated histologically into 15
subtypes[2]andclassiﬁedintothreegrades(I–III)according
to the World Health Organization (WHO) criteria, which
have been updated in 2007 [4, 5]: grade I meningiomas
which are benign, exhibit slow growth, and represent 90%;
grade II (atypical) and grade III (anaplastic) meningiomas,
representing about 6–8% and 2–4%, respectively, which have
a much more aggressive clinical behaviour and they are char-
acterized by rapid progression, recurrence, metastases, and
poor outcome [2]. More speciﬁcally, atypical meningiomas
have high mitotic index and presence of at least three of the
following four characteristics: sheeting architecture, hyper-
cellularity, macronuclei, and small cell formation. Anaplastic
meningiomas are characterized by excessive mitotic activity
and focal or diﬀuse loss of meningothelial diﬀerentiation at
the light microscopic level resulting in sarcoma, carcinoma
or melanoma-like appearance [5].
Brain invasion is a controversial criterion. Although it is
not formally a pathologic criterion for WHO grade II meni-
ngiomas; nevertheless, the diagnosis should mention it since
thebraininvasioncorrespondsprognosticallytoWHOgrade
II and its presence implies a greater likelihood of recurrence
[1].
Surgical resection of meningiomas is the prevalent
treatment. Moreover, radiation therapy has now attained a
standard role in the primary and adjuvant treatment settings
and is indeed the only commonly accepted form of adjuvant2 The Scientiﬁc World Journal
therapy after surgicalresection, although meningiomas have,
errantly, been regarded as radio resistant [6].
The risk of recurrence in operated meningiomas is
correlated with the histological grade, the degree of surgical
resection, the biological aggressiveness of the tumor, and
large tumor size [7]. Although in benign meningiomas sur-
gical resection is associated with a high cure rate, supposing
that the whole tumor is excised; however, there is always
considerable risk of recurrence (ranged between 9% and
32%) even after apparently complete resection with excision
of the surrounding dura and involved bone [8, 9]. On the
contrary, recurrence is very common in high-grade lesions,
even after total resection [10]. Biological aggressiveness of
meningiomas depends on various cellular characteristics
such as the proliferation activity, which is determined by the
expression of the nuclear antigen Ki-67 [11].
In the diagnostic workup of patients with meningiomas,
a combination of contrast-enhanced imaging techniques
such as Computed Tomography (CT) and Magnetic Res-
onance Imaging (MRI) is routinely used in deﬁning the
location and extent of tumour, as well as for long-term
followup. Although these imaging modalities could provide
a presumptive diagnosis, the histological diagnosis can only
be made postoperatively. Furthermore, this combination has
also limitations, especially at the skull base and in the case of
bony involvement, while in the case of suspected residual or
recurrenttumour,itcanbeverydiﬃculttodistinguishviable
tumour from scar tissue by CT or MRI [12].
Molecular Nuclear Medicine imaging techniques—Sin-
gle Photon Emission Computed Tomography (SPECT) and
Positron Emission Tomography (PET)—although not rou-
tinely used yet, could provide complementary information
to CT and MRI, to establish a noninvasive histological
diagnosis prior to operation, to distinguish between residual
or recurrent viable tumour and scar tissue and to estimate
treatment response in the postsurgical and postradiation
evaluation. In this purpose, various SPECT and PET radio-
pharmaceuticals have been used which provide information
aboutvariouscellularprocessesandbiologicalcharacteristics
of meningiomas (Table 1).
2. SPECTRadiopharmaceuticals
2.1. Thallium-201. Thallium-201 (201Tl) is a potassium ana-
logue possessing an aﬃnity for the sodium- and potassium-
activated adenosine triphosphatase (Na+-K+ ATPase) pump
and is distributed in potassium-rich organs, such as the
heart, kidney, gastrointestinal tract, and the thyroid gland,
but exhibits little uptake in the normal brain [13].
201Tl is known to accumulate in a variety of tumors, and
it was one of the ﬁrst radiotracers that have been used in the
area of oncology. 201Tl uptake in brain tumors depends on
regional blood ﬂow, Blood Brain Barrier (BBB)permeability,
cellular activity, and cell number [14].
201Tl uptake in meningiomas was thought mainly to
be related to lesional vascularity. Nevertheless, its retention
rates diﬀered according to histological types indicating that
vascularityitselfwouldnotcorrelatewithhistologicaltypeor
malignancy grade, and factors other than lesional vascularity
were involved. Mitotic or proliferation rates correlated to
cellular Na+-K+ ATPase activity would be a factor regu-
lating 201Tl uptake. It has been reported that long-lasting
retention of thallium in serial brain SPECT studies could
diﬀerentiate preoperatively intracranial meningiomas with
diﬀerent biological behaviour, predict malignant potential
of meningiomas, and provide information of meningioma
aggressiveness [15–17]. In a recent study by Takeda et al., a
signiﬁcant correlation was found between the 201Tl uptake
index in the delayed image and MIB 1 labeling index in
postoperative tumor specimens. Moreover, meningiomas
with strongly positive vascular endothelial growth factor
(VEGF) exhibited a signiﬁcantly higher 201Tl uptake index
compared to VEGF weakly positive meningiomas in both the
early image and the delayed image [18].
2.2. 99mTechnetium-Labelled Compounds. 99mTechnetium-
(99mTc-) labelled compounds have also been used in the
studyofmeningiomas.Thesewereprovedadvantageousover
201Tl, due to 140keV γ-ray energy, high photon ﬂux, higher
spatial resolution, less radiation burden to the patient, and
excellent availability.
99mTc-methoxyisobutylisonitrile (MIBI) is a common
radioligand for the evaluation of myocardial perfusion.
SPECT with 99mTc-MIBI has been proposed as a com-
plementary diagnostic tool for the evaluation of various
neoplasmsincludingbraintumours[19].Thecellularuptake
of positively charged MIBI ions is driven by the negative
electric potential generated on the inner surface of the
cellular membrane and particularly on the inner mitochon-
drial membrane [20]. 99mT c - M I B Iu p t a k ei sr e l a t e dt ot i s s u e
perfusion and normal cell membrane and mitochondrial
activity. It has been described by Petrovic et al. [21] that
meningiomas exhibit high perfusion index but low retention
index. This phenomenon was attributed to a relatively weak
ﬁxation of the radiopharmaceutical in benign meningioma
cells. The high metabolic rate of malignant cells generates
very high negative electrical potential along the inner surface
of their mitochondrial membranes that strongly attracts
MIBI cations. As the metabolic demands of meningioma
cells are much lower than those of malignant tumours,
the fraction of MIBI ions stranded in the mitochondria
is smaller than in malignant cells, and the larger fraction
is available to the washout mechanism. Hyperperfusion of
meningiomas can also facilitate the washout. Thus, it seems
likely that both the high uptake and the quick wash-out
of MIBI observed in meningioma are facilitated by the
abundant blood supply and the lack of BBB. Bagni et al.
[19] also noticed that 99mTc-MIBI uptake in meningiomas
was proportional to the tumour vascularity. It has also been
shown that high-grade brain tumors have increased 99mTc-
MIBI uptake compared with that of low-grade brain tumors.
99mTc-MIBI uptake was correlated with the percentage of the
S-phasefractionofthetumorcell(whichisareﬂectionofthe
proliferation potential of tumors) and the DNA aneuploidy
level (which is more common in malignant tumors). The
inactive, nonviable, apoptotic, or necrotic tumour cells doThe Scientiﬁc World Journal 3
Table 1: SPECT and PET radiopharmaceuticals used in meningiomas.
Tracer Imaging modality Advantages Disadvantages References
Thallium-201 SPECT, analog of K+ Information of tumor biological
characteristics
Limited imaging properties,
serial brain SPECT studies [15–18]
99mTc-labeled compounds
SPECT, tissue
perfusion, cell
membrane integrity,
and mitochondrial
activity
Viability marker, prediction of
anticancer drug resistance related
to Pgp
Small series of patients, the
correlation between tracer
uptake and tumor grading or
other biological
characteristics, needs
validation with further studies
[19, 21–28]
111In-octreotide and
99mTc-depreotide SPECT, SSTR
High sensitivity and negative
predictive value, diﬀerential
diagnosis from somatostatin
receptor-negative and orbital
tumours, diﬀerentiation between
postoperative scar and
recurrence, selection of patients
for somatostatin analogue-based
therapies
Speciﬁcity depends on the
BBB integrity, diﬃculty in
detecting small tumors,
limited imaging properties of
111In, few studies with
99mTc-depreotide
[42–59, 65]
18F-FDG PET, brain glucose
metabolism
Prognostic information
(prediction of recurrence and
survival)
High uptake in normal gray
matter not tumor speciﬁc [44, 66–73]
11Co r18F labeled amino acids PET, protein synthesis
High tumor/background ratio,
identiﬁcation of skull base
meningiomas, improve target
volume deﬁnition for RT
Not useful for grading [67, 76–83]
11C-choline PET, phospholipid
synthesis Meningioma grading Few studies [87, 88]
1-11C-acetate PET
Accurate tumor delineation,
guiding the stereotactic biopsy,
optimizing treatment planning
before radiosurgery
Not useful for grading, few
studies [72]
13N-NH3 PET, analog of K+ High tumor/background ratio Not useful for grading, Few
studies [99]
68Ga-DOTATOC PET, SSTR
High tumor/background ratio,
identiﬁcation of skull base and
en plaque meningioma and local
osseous invasiveness,
improvement of target volume
deﬁnition for RT, recurrent
disease, selection of patients for
hormonal treatment or the use of
DOTATOC labelled with
β-emitting radionuclides
Uptake in parasellar lesions [102, 103,
105–111]
Pgp: P-glycoprotein, SSTR: somatostatin receptors, BBB: Blood Brain Barrier, RT: Radiation Treatment.
not take up the radioligand and that is why it is sometimes
referred to as the viability marker [22].
In malignant tumors the uptake of 99mTc-MIBI has also
been associated with the presence of P-glycoprotein (Pgp) in
the cell membrane which is related to the multidrug resistant
gene [23]. Kunishio et al. evaluated whether 99mTc-MIBI
SPECT characteristics of intracranial meningioma were cor-
related with the histological malignancy, proliferative poten-
tial,andPgpexpression,encodedbythemultidrugresistance
gene-1 (MDR-1) messenger ribonucleic acid (mRNA). They
found that 99mTc-MIBI may not be useful for determining
proliferativepotentialandhistologicalmalignancy,butcould
predict anticancer drug resistance related to the expression
of MDR-1 mRNA and its gene product Pgp in patients with
intracranial meningiomas [24].
99mTechnetium—tetrofosmin (99mTc-TF)—a lipophilic
cationic diphosphine, which is routinely used for myocardial
perfusion imaging, displays tumor-seeking properties, too.
Its uptake mechanism is similar to 99mTc-MIBI, depending
mainly on regional blood ﬂow and cell membrane integrity.
99mTc-TF enters cells mainly via passive transport driven
by the negative potential of the intact cell membrane and4 The Scientiﬁc World Journal
Figure 1: Transverse slices of a 99mTc-tetrofosmin SPECT brain
study in a patient with meningioma showing increased tracer
uptake by the tumor.
localizes mostly within the cytosol and only a fraction enters
themitochondria[25].Inthehealthybrain,uptakeof 99mTc-
TF is seen in the choroid plexuses, pituitary gland, and scalp,
but not in the normal brain parenchyma, since it does not
cross the intact BBB [26].
In a small series of studies, 99mTc-TF uptake in menin-
giomas was correlated with cellular proliferative activity
(assessed either immunohistologically by the Ki-67 index or
by ﬂow cytometry) and tumor grading (Figure 1)[ 27, 28]. A
signiﬁcant correlation of 99mT c - T Fu p t a k ewi t hp r o l i f e ra t i o n
index and tumor grade was found. Anaplastic meningiomas
tended to exhibit a higher radiotracer uptake as compared
to typical ones without any overlapping of 99mTc-TF uptake
between them. Likewise, meningiomas with higher prolif-
eration index tended to exhibit increased 99mTc-TF uptake.
Furthermore, it was also found a signiﬁcant correlation of
99mTc-TF uptake with risk of recurrence at 1 year postopera-
tively. Thus the authors stated that 99mTc-TF brain SPECT
may hold a role in distinguishing typical from anaplastic
meningiomaspreoperatively,adiscriminationthatisdiﬃcult
by CT or classic MRI, and that this ﬁnding would also
be of great importance in patients in which surgery is not
an option, due to tumor localization, or when there is a
medical disorder that could increase the potential morbidity
ofsurgicalexcision.Nevertheless,alimitationofthesestudies
was the absence of grade II meningiomas in the study
population.
2.3. Somatostatin Receptor Scintigraphy. Somatostatin—a
cyclic tetradecapeptide neuropeptide—is the most widely
distributed of the hypothalamic releasing hormones in the
central nervous system and in the periphery, including the
pancreas, gut, and pituitary [29]. In the brain, somatostatin
is believed to act as a neurotransmitter and neuromodulator
[30]. The eﬀects of somatostatin are mediated by trans-
membrane domain G-protein coupled receptors. In vivo
and in vitro studies have shown that somatostatin receptors
(SSTRs) are expressed on the cell membrane of various
central nervous and peripheral tissues in high density to a
varying extent, including tumours of neuroendocrine origin
and intracranial tumours [31]. Molecular biologic research
revealedthatvarioustypesofSSTRsexist.Todate,5diﬀerent
SSTRs subtypes are known, SSTR1–SSTR5, with subtype
speciﬁcity for distinct histology [32, 33]. Of these, subtype 2,
SSTR2, is most often expressed on the surface [34–36]. Two
isoforms of SSTR2 have been isolated, SSTR2A and SSTR2B,
which diﬀer in size and the sequence of their intracellular
COOH-terminal domain [37].
Figure 2: Fused SPECT/CT images of somatostatin receptor scin-
tigraphy demonstrating increased tracer uptake in a patient with
anaplastic meningioma [67].
It is now well known that leptomeninx express SSTRs
[38].Meningiomas,whichoriginatefromthearachnoidlayer
of the leptomeninx, usually have a high SSTR2 density [39].
Clinical nuclear medicine has taken advantage of this
characteristic, making the in vivo detection of SSTRs pos-
sible. Somatostatin receptor scintigraphy (SSRS) became an
invaluable tool used extensively in routine management of
patients with meningiomas.
As endogenous somatostatin has a very short biologic
half-life (∼2min), it is rapidly cleared from the blood; thus,
somatostatin itself cannot be used as an imaging agent
in nuclear medicine. To overcome this drawback, a long-
acting analog of somatostatin consisting of 8 amino acids
was developed. This octapeptide exhibits a biologic half-life
on the order of several hours and can be linked through
diethylenetriaminepentaacetic acid to indium-111 (111In),
forming the well-known radiotracer [111In]octreotide [40].
Although all receptors bind natural somatostatin with
high aﬃnity; nevertheless, they diﬀer in their binding char-
acteristics to long-acting somatostatin analogues. Whereas
SSTR2,SSTR3,andSSTR5exhibithighaﬃnityforoctreotide
[41], the frequent overexpression of the SSTR2A receptor
may explain the high tracer uptake observed in meningioma
patients during SSRS [42].
SSRS does not reveal increased tracer uptake by the
normal leptomeninx, although the latter contains SSTRs.
Since octreotide is a polar, water-soluble peptide that does
not penetrate the intact BBB, SSRS can only demonstrate
somatostatin receptor positive intracranial lesions if the BBB
isdisrupted.Onlymeningiomas—locatedoutsidetheBBB—
usually demonstrate high tracer uptake, while intracranial
tumours may be out of reach due to the BBB and therefore
may not be detectable by SSRS [43, 44].
Meningiomas visualization with 111In-octreotide de-
pends on the expression of SSTR2 on meningioma cells—
as shown by the reverse transcriptase polymerase chain
reaction—[45], as well as on the tumor volume [46].
Although many studies have reported detection of all
meningioma lesions with a sensitivity almost 100% [47–
50]a n dv a r i e d111In-octreotide uptake (Figure 2); however, a
major drawback of 111In-octreotide SPECT is its diﬃculty in
detecting meningiomas with a diameter <2.7cm or a volume
<10mL [51]. A signiﬁcant correlation between meningioma
volume and grade of tracer uptake was found, with higherThe Scientiﬁc World Journal 5
uptake grade in larger tumours. Howbeit, depending on
location and receptor status, even small tumours with
volumes of 5mL demonstrated intense tracer uptake [46].
Despite the high sensitivity of 111In-octreotide scintigraphy
for the diagnosis of meningiomas, speciﬁcity may be low
depending on the presence of lesions which disrupt the BBB,
such as cerebral metastases [44]. Nevertheless, the method
provides high negative predictive value (100%).
Due to the high SSTRs density, meningiomas of the skull
base or the orbit may be diﬀerentiated from somatostatin
receptor-negative tumours using 111In-octreotide scintigra-
phy. Neurinomas and neuroﬁbromas do not express somato-
statin receptors, thus they do not demonstrate tracer uptake,
making 111In-octreotide scintigraphy a useful technique
in the diﬀerential diagnosis from multiple meningiomas
[52, 53].
SSRS seems to be an additional valuable tool with high
sensitivity and speciﬁcity for optimizing the diagnosis of
optic nerve sheath meningiomas from other orbital tumors
(such as vascular lesions, non-hodgkin lymphomas, optic
nerve gliomas, idiopathic orbital inﬂammation), without the
need for more invasive procedures. It has been reported
that the 111In-octreotide uptake ratios of meningiomas were
signiﬁcantly higher than those of other subgroups of orbital
tumors, except for adenocarcinomas [54].
SSRS may also aid in the diﬀerentiation between post-
operative scar and meningioma recurrence. The risk of local
recurrence is wellknown, especially for meningioma located
near the skull base where meninges are attached very closely
to the bones, thus rendering total resection of meningioma
diﬃcult. In the ﬁrst 6 months after surgery, in a reasonable
number of patients, MRI may fail to diﬀerentiate between
tumor remnants or recurrent meningioma and nonspeciﬁc
hyperperfusion. The high tumour 111In-octreotide uptake
seen in SSRS in most meningiomas may be of clinical
relevance for exact tumour delineation in cases of tumour
recurrence [55–58].
IthasbeenreportedthatthecorrelationbetweenSSTR2A
immunoexpression and the histological grade, according
to the WHO 2007 classiﬁcation, as well as microvessel
density of the tumors, has demonstrated that atypical and
anaplastic meningiomas characterized by a higher microves-
sel density. This ﬁnding would provide the basis for the
use of somatostatin analogue-based therapies, which have an
antiangiogenic eﬀect,inthetreatmentofthesetumours[59].
Nevertheless, in a small number of pathologically proven
meningiomas, Nathoo et al. reported that there was no
diﬀerence in intensity of octreotide uptake related to the
histologic subtype of meningiomas [44].
The limited imaging properties using a medium-energy
isotope, such as 111In, explain the reduced sensitivity in
detecting meningiomas with a volume of less than 10mL
so that SSTRs imaging with higher resolution is desirable.
An e w99mTc-labeled somatostatin analog, 99mTc-depreotide,
was developed and approved in the United States and Europe
for diagnostic use in lung nodules [60].
The binding proﬁle of this new tracer shows high aﬃnity
to subtypes 2, 3, and 5 of the SSTRs, with dissociation
constants (Kd) in the order of 1.5 to 2.5nmol/L [61]. There-
fore, it is similar to 111In-octreotide, which binds to SSTRs
subtypes 2 and 5 with high aﬃnity (Kd, 0.1 to 5nmol/L),
to subtype 3 with moderate aﬃnity (Kd, 10 to 100nmol/L),
b u td o e sn o tb i n dt oS S T Rs u b t y p e s1a n d4[ 62]. Compared
with 111In-octreotide, the use of 99mTc-depreotide has the
advantage of a lower radiation dose due to the faster decay
and lower photon energy of the isotope, resulting in an
eﬀective dose estimate of 0.023mSv/MBq [63] instead of
0.08mSv/MBq for 111In [64]. Furthermore, the cost of the
99mTc-labeledradiopharmaceuticalislessandtherearefewer
requirements for the imaging equipment and the radiation
protection facilities compared with those required when the
octreotide analog labeled with the medium-energy isotope
111In is used. Labeling of the ligand is easy and generator
produced 99mTc ensures its continuous availability.
99mTc-depreotide SPECT has been used for the evalua-
tion of intraorbital and extracranial recurrent meningioma
in comparison with 111In-octreotide and revealed a smaller
extracranial site of recurrence, not detected on 111In-
octreotide scintigraphy, as a result of the better resolution
that can be achieved with that isotope [65].
3. PET Radiopharmaceuticals
3.1. 18F-2-Fluoro-2-deoxy-D-glucose. 18F-2-ﬂuoro-2-deoxy-
D-glucose (18F-FDG) is used for the study of brain glucose
metabolism. It is transported into the cells by facilitated
diﬀusion, then phosphorylated to FDG-6-PO4 and trapped
intracellularly where it can be measured. 18F-FDG was one
of the ﬁrst PET tracers used in the study of meningiomas
although with conﬂicting ﬁndings in the literature. Some
authors have described high 18F-FDG uptake in menin-
giomas, similar to normal gray matter, whereas others
reported hypometabolic features resulting in low tumor-
to-gray matter-ratio [66–68]. It has been proposed that
these diﬀerences may be attributed to diﬀerences in glucose
consumption in tumors with diﬀerent biological features
(Figure 3). 18F-FDG uptake was proposed as an index of
tumor aggressiveness and it has been correlated with the
probability of recurrence and patients’ survival [66, 69, 70].
It has been reported that the highest glucose utilization rate
among intracranial meningiomas was seen in atypical, pap-
illary and recurrent meningiomas [44, 66]o ri ng r a d e2a n d
3 meningiomas (according to previous WHO classiﬁcation)
as compared with grade 1 meningiomas in tumors of high
cellularity [69]. Especially for WHO Grade 1 meningioma
18F-FDG PET seems not useful for tumor delineation, which
mightbefurthertroubledbyperitumoraledema[66,70,71].
Cremerius et al. reported that recurrent meningioma exhib-
ited more intense FDG uptake than grade 1 meningioma
as compared with gray matter [70] .I nar e c e n ts t u d y ,L i u
et al. found 18F-FDG PET neither useful for exact tumor
delineation nor for monitoring response to radiosurgery
[72]. However, they described that 18F-FDG may be valuable
for diﬀerentiating benign from malignant meningioma. In
contrast,LeeandcoworkersstatedthatthesensitivityofFDG
PET to detect high-grade meningioma was low, but 18F-FDG6 The Scientiﬁc World Journal
Figure 3: 18F-FDG PET study in a patient with anaplastic menin-
gioma. Increased FDG uptake in the primary tumor (left temporal
r e g i o n )a sw e l la si ni t sp u l m o n a r ym e t a s t a s e s[ 67].
uptake correlated signiﬁcantly with the proliferative activity
ofmeningiomas.Theauthorssuggestedthat 18F-FDG uptake
could be one of the signiﬁcant prognostic factors and that its
role would rather be to predict recurrence and survival [68].
Nevertheless, the major drawback of 18F-FDG is its
high uptake in normal gray matter. Thus, in slow growing
tumors such as meningiomas—which may exhibit a mod-
erately increased glucose metabolism—18F-FDG PET may
notreliablydetectthem.Furthermore, 18F-FDGisnottumor
speciﬁc,sincehighuptakehasalsobeenobservedininfection
or inﬂammation [73]. Therefore, other tracers have been
tested.
4.PETTracersBeyond FDG
4.1. Amino Acids. The rationale to use amino acids in
proliferating cells is based on an upregulation of amino acid
transport resulting in a high tumor to normal tissue ratio—
even in slow growing tumors [74, 75]. Several labelled amino
acids have been used in the study of meningiomas such as
[11C]-methionine (11C-MET) and [2-18F]-ﬂuoro-L-tyrosine
(18F-TYR).
11C-MET is a marker of amino acid transport as well
as protein synthesis and shows high uptake in meningioma
(tumour to cerebellum ratios 2.62–5.37, mean 3.63) [67, 76–
78]. As there is a comparatively low uptake in normal white
and gray matter, it allows better delineation of meningioma
from normal structures than 18FDG [79]. Astner et al.
reported its use in planning stereotactic radiotherapy of skull
base WHO I and WHO II meningiomas [80]. They found
thattheadditionof 11C-METPETinthedelineationofGross
Tumor Volume (GTV) resulted in an enlargement of GTV
of 9.4% ± 10.7% since the method detected small tumor
portions that were not identiﬁed by CT or MRI. Thus they
concludedthattheintegrationofthemethodinradiotherapy
treatment planning could be beneﬁcial for the management
of patients. It has been reported that 11C-MET uptake is
not correlated with aggressiveness and WHO grading of
meningiomas [79, 81], although Iuchi et al. found that 11C-
MET uptake signiﬁcantly correlated with proliferative tumor
activity (Ki-67 index) [82].
18F-TYR is another marker of L-amino acid transport
protein synthesis and accumulates signiﬁcantly in menin-
gioma (tumor-to-cortex activity ratio of about 2.5). The
uptake in normal gray and white matter is low, but high
in oropharyngeal mucosa and salivary glands. 18F-TYR was
used for the discrimination of meningioma from healthy
tissue, especially in diﬃcult locations such as the skull base,
and the delineation of tumor compared to that seen on MRI
[83]. It was found that 18F-TYR PET could clearly identify
meningiomas of the base of the skull even after irradiation,
while the metabolic lesions were not exactly matched with
the MRI ﬁndings. The clinical signiﬁcance of this ﬁnding
should be clariﬁed in further studies in order to deﬁne the
role of 18F-TYR in treatment planning.
4.2. 11C-Choline. 11C-Choline is a marker of phospholipid
synthesis, which is increased in malignant tumors. It has
been used for imaging of various tumors including prostate
cancer and brain tumors [84, 85]. The uptake of 11C-choline
in the normal brain is negligible, allowing good delineation
of brain tumor contours and diagnosis of tumor recurrence
[85]. Meningiomas have exhibited, in in vitro and imaging
studies, altered choline metabolism [86]. Preliminary results
of the use of 11C-choline PET in meningiomas demonstrated
excellent visualization of all lesions [87, 88]. Giovacchini et
al. [88] showed in a preliminary clinical study including 7
meningioma patients (WHO I = 5, WHO II = 2) that
11C-choline may better image meningioma compared to
FDG.Furthermore,itwasfoundthat 11C-cholineuptakewas
higher in grade II than in grade I meningiomas, indicating
that 11C-choline uptake may reﬂect the proliferation rate of
the tumors and it could be used for meningioma grading.
However, the potential of this tracer remains unclear and
further studies are needed to conﬁrm these ﬁndings as well
as to assess the clinical use of the tracer in the management
of meningioma.
4.3. 1-11C-Acetate. 1-11C-Acetate has been used for the de-
tection of several tumors such as prostate and lung cancer,
hepatocellular carcinoma and astrocytomas [89–92]. The
possible mechanisms of 1-11C-acetate uptake by tumor cells
include impaired tricarboxylic acid cycle activity or anabolic
pathways of fatty acid and sterol synthesis [93, 94]. In the
brain, acetate is preferentially metabolized by astrocytes, and
labeled acetate has been used to assess glial metabolism
and glial-neuronal interactions [95]. Metabolic data derived
from a small set of tumors revealed that glioblastoma and
meningioma clearly can convert 14C-acetate into acidic and
amino acid metabolites, presumably through the oxidative
pathwayofthetricarboxylicacidcycle.InastudybyLiuetal.,
it was found that 1-11C-acetate was useful for detecting and
evaluating the extent of meningioma and potentially useful
for monitoring the response to radiosurgery. The authors
suggestedthataccuratetumordelineationwith1-11C-acetateThe Scientiﬁc World Journal 7
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Figure 4: 68Ga-DOTATOC PET (a) and fused PET/CT (b and c) images of a skull base meningioma with orbital invasion and close relation
to the sella turcica region. Physiological tracer uptake of the pituitary gland [106].
PET is of potential value for guiding the stereotactic biopsy
and for optimizing treatment planning before radiosurgery.
However, they found that 1-11C-acetate was not helpful for
grading the tumor [72].
4.4. 13N-NH3 PET. There are 2 chemical forms of ammonia
(NH3 and NH4
+) in the blood. The relative proportion
of NH3 and NH4
+ in blood is determined by the pH.
The majority of blood ammonia is in the form of NH4
+
at a normal pH of 7.3 to 7.4. Similar to Tl-201, (13)N-
(13)NH(4)(+) is an analog of K(+) and could substitute
K(+) in some cases because they have similar hydrated
radius [96]. It has been reported that cerebral astrocytomas
exhibit a substantial uptake of 13N-NH3 and 13N-NH3 might
be a promising tracer for separating radiation necrosis
from astrocytoma recurrence [97, 98]. Recently, 13N-NH3
has been used in the study of meningiomas by Xiangsong
et al. [99]. These preliminary results indicate that 13N-NH3
allows better detection and evaluation of the extent of
meningiomas in comparison with FDG, oﬀering excellent
imaging properties and a very high tumor-to-background
ratio. The brain uptake of 13N-NH3 is limited due to its low
lipid solubility which does not permit passage through the
intact BBB. The location of meningiomas outside the BBB
results in higher accumulation of the tracer in these tumors
than in the normal brain cortex. Nevertheless, 13N-NH3
uptake was not useful for diﬀerentiating benign (Grade I)
from atypical (Grade II) meningiomas.
4.5. 68Ga-DOTATOC. The last decade, the somatostatin
analog DOTA-D-Phe1-Tyr3-octreotide (DOTA-TOC) has
been developed [100]. 1,4,7,10-tetraazacyclododecane-
N,N9,N0,N-tetraacetic acid (DOTA) is a macrocyclic
chelator that ensures high in vivo stability for the corre-
sponding radiometal chelates. Moreover, the replacement of
Phe3 by Tyr in the octapeptide increases its hydrophilicity
and thus the eﬃciency of its clearance by the kidney. DOTA-
TOC has been labelled with the positron emitter 68Ga. This
new radiotracer, 68Ga-DOTATOC, shows a high aﬃnity
(half-maximal inhibitory concentration [IC50] = 14nmol/L)
for human SSTR2 [101] and exhibits several advantages over
conventional 111In-octreotide [102]. The coincidence detec-
tion of two photons generated by annihilation of the emitted
positron by a modern PET scanner facilitates a geometric
resolution in the order of 4–6mm, and biodistribution
can be quantiﬁed in (patho)physiologic terms. Because of
the increased spatial resolution and the ability to quantify
biodistribution, PET is desirable for SSTR imaging.
68Ga-DOTATOC PET showed a high meningioma/back-
ground ratio [102, 103]. Henze et al. [102, 103]r e p o r t e d
high-contrast images of meningiomas measuring only 7-
8mm in diameter, which could be clearly separated both
from surrounding brain and bone tissue. This capability is
importantsincemeningiomasmaycauseseriousproblemsto
the neurosurgeon because of their tendency to local osseous
invasiveness. Especially at the skull base, where biopsy has
a high risk of hemorrhage and the ﬁndings of CT and MRI
are often unclear [9, 104], PET provides valuable additional
information regarding the extent of meningiomas located
beneath osseous structures. A similar diﬃculty arises with
en plaque meningioma [105], where the surgeon has to limit
the resection to a reasonable degree. Therefore, preoperative
evaluation of meningioma with 68Ga-DOTATOC PET, or
more ideally, fused PET/CT or PET/MRI imaging, would
inﬂuence surgical strategy and increase the accuracy of
surgical resection. However, one limitation is the parasellar
region, because of the pituitary gland expressing SSTR2
(Figure 4)[ 106, 107]. 68Ga-DOTATOC also allows detection
of additional lesions in patients with multiple meningiomas
[107].
The ability of 68Ga-DOTATOC for adequate delineation
of meningiomas has proven useful for radiation treatment
planning of these tumors [106–109]. It has been reported
that 68Ga-DOTATOC-PET/CT information may strongly
complementanatomicaldatafromMRIandCTandimprove
target volume deﬁnition especially in cases with complex
meningioma such as skull base manifestations, osseous
inﬁltration, and recurrent disease after surgery. Radiation
targeting with fused 68Ga-DOTATOC PET, CT, and MRI
resulted in signiﬁcant alterations in target deﬁnition in 73%
of patients [109].8 The Scientiﬁc World Journal
68Ga-DOTATOC may be used for the evaluation of
alternative therapeutic approaches in cases of nonoperable
meningiomas. Pretherapeutic knowledge of the receptor
statusisessentialforboth,eithertheapplicationofhormonal
treatment or the use of DOTATOC labelled with β-emitting
radionuclides, a ﬁeld of nuclear medicine in which interest
has been growing rapidly in the past few years [110, 111].
5. Conclusion
The contribution of SPECT and PET molecular imaging
in the noninvasive diagnosis and diﬀerential diagnosis,
response to treatment, and target delineation for radiation
therapy of meningioma, is well described. SPECT and PET
may also help in the detection of early metabolic changes,
which precede anatomical changes revealed by CT and MRI,
and identify metabolically active and aggressive tumor areas,
which should be treated appropriately.
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